These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6433043)

  • 1. Verapamil enhancement of chemotherapeutic efficacy in human bladder cancer cells.
    Simpson WG; Tseng MT; Anderson KC; Harty JI
    J Urol; 1984 Sep; 132(3):574-6. PubMed ID: 6433043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced lethality by methylxanthines in human bladder cancer cells treated with thiotepa.
    Fingert HJ; Kindy RL; Pardee AB
    J Urol; 1984 Sep; 132(3):609-13. PubMed ID: 6433047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verapamil enhanced in vitro chemosensitivity of a murine bladder carcinoma, FCB.
    Ballou RJ; Simpson WG; Harty JI; Tseng MT
    Urol Res; 1986; 14(4):195-200. PubMed ID: 3097900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy.
    Pu YS; Hsieh TS; Cheng AL; Tseng NF; Su IJ; Hsieh CY; Lai MK; Tsai TC
    Br J Urol; 1996 Jan; 77(1):76-85. PubMed ID: 8653321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer.
    Seraphim LA; Perrapato SD; Slocum HK; Rustum YM; Huben RP
    J Urol; 1991 Mar; 145(3):613-7. PubMed ID: 1900087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Low-grade, low-stage transitional carcinoma of the bladder. Analysis of 147 cases].
    Escudero Barrilero A; Gutiérrez Sanz-Gadea C; Hernández Fernández C; Mateos Torres A; Maganto Pavón E; Mayayo Dehesa T
    Actas Urol Esp; 1985; 9(2):135-46. PubMed ID: 3925729
    [No Abstract]   [Full Text] [Related]  

  • 7. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of verapamil on a multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent.
    Long JP; Prout GR; Wong YK; Lin CW
    J Urol; 1990 May; 143(5):1053-6. PubMed ID: 2329596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical chemotherapy in a controlled trial with thio-tepa versus doxorubicin hydrochloride.
    Horn Y; Eidelman A; Walach N; Ilian M
    J Urol; 1981 May; 125(5):652-4. PubMed ID: 6785455
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro chemosensitivity of human bladder cancer.
    Weisenthal LM; Lalude AO; Miller JB
    Cancer; 1983 Apr; 51(8):1490-6. PubMed ID: 6186358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity.
    Mizutani Y; Okada Y; Yoshida O; Fukumoto M; Bonavida B
    Cancer; 1997 Mar; 79(6):1180-9. PubMed ID: 9070496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical chemotherapy: combination with Tween 80 increases cytotoxicity in vitro.
    Parris CN; Masters JR; Walker MC; Newman B; Riddle P; English P
    Urol Res; 1987; 15(1):17-20. PubMed ID: 3103302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein expression in bladder cancer.
    Park J; Shinohara N; Liebert M; Noto L; Flint A; Grossman HB
    J Urol; 1994 Jan; 151(1):43-6. PubMed ID: 7902877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro chemotherapy testing of transitional cell carcinoma.
    Shrivastav S; Paulson DF
    Invest Urol; 1980 Mar; 17(5):395-400. PubMed ID: 6153642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemosensitivity in established human bladder carcinoma and HELA cell lines in vitro].
    Uchibayashi T
    Nihon Hinyokika Gakkai Zasshi; 1983 Sep; 74(9):1606-20. PubMed ID: 6202921
    [No Abstract]   [Full Text] [Related]  

  • 16. Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma.
    Zhang H; Guo Y; Song Y; Shang C
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):49-55. PubMed ID: 27878359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer.
    Harris NM; Duffy PM; Crook TJ; Anderson WR; Sharpe P; Hayes MC; Cooper AJ; Solomon LZ
    BJU Int; 2002 Dec; 90(9):957-64. PubMed ID: 12460364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytostatic sensitivity and MDR in bladder carcinoma cells: implications for tumor therapy.
    Schuldes H; Dolderer JH; Schoch C; Bickeböller R; Woodcock BG
    Int J Clin Pharmacol Ther; 2000 Apr; 38(4):204-8. PubMed ID: 10783830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical and systemic chemotherapy of murine bladder cancer.
    Soloway MS
    Cancer Res; 1977 Aug; 37(8 Pt 2):2918-29. PubMed ID: 406041
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined thiotepa and mitomycin C instillation therapy for low-grade superficial bladder tumor.
    Hu KN; Kim A; Khan AS; Soroff H; Gonder M
    Cancer; 1985 Apr; 55(8):1654-8. PubMed ID: 3156664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.